Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer

Basit Öğe Kaydı
dc.authorid0000-0002-8049-7867en_US
dc.contributor.authorBayraç, Abdullah Tahir
dc.contributor.authorAkça, Oya Ercan
dc.contributor.authorEyidoğan, Füsun İnci
dc.contributor.authorÖktem, Hüseyin Avni
dc.date.accessioned2019-12-06T21:15:36Z
dc.date.available2019-12-06T21:15:36Z
dc.date.issued2018
dc.departmentKMÜ, Mühendislik Fakültesi, Biyomühendislik Bölümüen_US
dc.descriptionWOS:000426370500010en_US
dc.descriptionPubMed:29485118en_US
dc.description.abstractTargeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-172 glioblastoma cell-line-specific single stranded DNA (ssDNA) aptamer in which the chemotherapeutic agent Doxorubicin (DOX) had been conjugated. DNA aptamer, GMT-3, was previously selected for specific recognition of glioblastoma and represented many advantageous characteristics for drug targeting purposes. Flow cytometry analysis proved the binding efficiency of the specific aptamer to tumour cell lines. Cell-type-specific toxicity of GMT-3:DOX complex was showed by XTT assay and terminated cytotoxic effects were screened for both target cell and a control breast cancer cell line. The result of this contribution demonstrated the potential utility of GMT-3 aptamer-mediated therapeutic drug transportation in the treatment of gliomas specifically. It was concluded that aptamer-mediated drug delivery can be applied successfully for clinical use.en_US
dc.identifier.citationBayraç, A. T., Akça, O. E., Eyidoğan, F. I., Öktem, H. A. (2018). Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer. Journal of Biosciences.
dc.identifier.doi10.1007/s12038-018-9733-x
dc.identifier.endpage104en_US
dc.identifier.issn0250-5991
dc.identifier.issn0973-7138
dc.identifier.issue1en_US
dc.identifier.pmid29485118
dc.identifier.scopus2-s2.0-85041117845
dc.identifier.scopusqualityQ1
dc.identifier.startpage97en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s12038-018-9733-x
dc.identifier.urihttps://hdl.handle.net/11492/2652
dc.identifier.volume43en_US
dc.identifier.wosWOS:000426370500010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Sceince
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBayraç, Abdullah Tahir
dc.language.isoen
dc.publisherIndian Acad Sciencesen_US
dc.relation.journalJournal of Biosciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectA-172en_US
dc.subjectAptameren_US
dc.subjectDoxorubicinen_US
dc.subjectGlioblastomaen_US
dc.subjectGMT-3en_US
dc.subjectXTTen_US
dc.titleTarget-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptameren_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bayrac, Abdullah Tahir 2018.pdf
Boyut:
915.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Mühendislik Fakültesi, Biyomühendislik Bölümü, Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu